Unternehmensübersicht
Imunon, Inc. operates as a clinical-stage biotechnology entity dedicated to the development of immunotherapies and vaccines, with its primary strategic focus directed toward localized treatment protocols for ovarian cancer. The company functions within the healthcare sector and specifically the biotechnology industry, a domain characterized by significant research and development expenditures aimed at advancing novel therapeutic mechanisms for oncology indications. As of the latest available data, the enterprise possesses a market capitalization of $12.28M, while specific annual revenue figures and total employee counts are not currently disclosed in the provided financial records. The modest market cap relative to the high-risk nature of clinical-stage biotechnology development indicates a valuation that is heavily dependent on the successful progression of its lead clinical program, IMNN-001, which is currently in Phase II development, rather than established commercial earnings or a large-scale operational infrastructure.
Finanzielle Gesundheit
The company reports a net income of $-14,495,028 and an EBITDA of $-14,358,786 for the trailing twelve months, while annual revenue data is not disclosed; the substantial negative gap between the reported net income and EBITDA figures suggests that non-operating expenses or significant interest costs are impacting the bottom line, although the precise revenue figure necessary to calculate a meaningful gross margin is unavailable in the current dataset. Free cash flow stands at $-8,529,147, indicating a capital-intensive burn rate typical for pre-revenue biotechnology firms that must allocate substantial liquidity toward clinical trials and research activities rather than generating operational cash flow. The reported gross margin, operating margin, and profit margin are all listed at 0.0%, which mathematically reflects the absence of recognized revenue in the trailing twelve-month period, confirming the company's status as a pre-commercial entity with no current sales history. On the balance sheet, the company holds $8.78M in cash assets against $1.01M in debt, resulting in a debt-to-equity ratio of 14.29, which presents a highly leveraged profile when viewed through traditional ratios, though the absolute debt burden remains manageable given the available cash reserves. The current ratio is recorded at 2.32, suggesting that the company maintains a conservative liquidity position with current assets significantly exceeding current liabilities, providing a buffer against short-term obligations despite the lack of revenue. Return on equity is reported at -256.4% and return on assets at -83.2%, metrics that reveal the company is currently destroying shareholder value and utilizing assets inefficiently in the absence of commercial product sales, a common characteristic for early-stage clinical companies before market entry.
Bewertungsanalyse
The trailing twelve-month P/E ratio is listed as N/A due to the company's lack of positive net income, while the forward P/E is recorded as -1.00, a metric that implies earnings are projected to remain negative in the near term rather than indicating a positive earnings trajectory. The price-to-book ratio is valued at 1.30, indicating that the market capitalizes the company at 130% of its book value, a premium that reflects the potential intrinsic value of its intellectual property and clinical pipeline rather than tangible asset backing. Price-to-sales and EV/EBITDA metrics are also listed as N/A or -0.31 respectively, where the negative EV/EBITDA of -0.31 further underscores the financial reality of a firm with no revenue generation and negative earnings before interest, taxes, depreciation, and amortization. The stock has exhibited significant price volatility, trading between a 52-week high of $41.22 and a 52-week low of $2.52, placing the current trading price well below the recent peak and reflecting the high risk premium associated with clinical-stage biotech assets. The beta value is 2.12, which signifies that the stock's price movements are more than twice as volatile as the broader market, highlighting the sensitivity of the share price to market sentiment and specific sector developments without the stabilizing influence of consistent dividend payouts or revenue streams.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, which accurately reflects the company's stage of development where historical year-over-year comparisons are not applicable due to the absence of commercial revenue or consistent earnings history. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the entity follows a strategy of reinvesting all available resources into research and development to advance its clinical programs rather than distributing income to shareholders. The overall growth and income profile is defined by a reliance on future clinical milestones and regulatory approvals to transition from a cash-burning research entity to a revenue-generating pharmaceutical company, with current financial performance entirely dependent on the successful execution of the IMNN-001 clinical trial program.